P&U Seeks Approval For Inhaled Nicotine
Pharmacia & Upjohn has filed a New Drug Application with the US Food and Drug Administration for its Nicotrol Nicotine Inhalation System. Subject to approval by the FDA, the Nicotine Inhalation System, for smoking cessation, will be marketed in the USA by the McNeil Consumer Products arm of Johnson & Johnson.
P&U has recently received approvals for the Nicotine Inhalation System from regulatory agencies in Italy and Denmark for over-the-counter sale. The product will be marketed in Europe under the Nicorette brand, which has been firmly established by P&U. The company expects approvals in other European countries by the end of 1996.
Marketing and product launch plans for the USA and also Europe are currently being finalized and will be announced by the firm "in the near future," according to McNeil.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze